Eur Heart J. 2008 Nov;29(21):2660-8.
Hormone therapy and risk of myocardial infarction: a national register study.
Løkkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard Ø.
Gynaecological Clinic, Rigshospitalet, Copenhagen Ø, Denmark.
Comment in: Womens Health (Lond Engl). 2009 Jan;5(1):29-31.
AIM: To assess the risk of myocardial infarction (MI) as a result of hormone therapy (HT), with focus on the influence of age, duration of HT, various regimens and routes, progestagen type, and oestrogen dose. METHODS AND RESULTS: All healthy Danish women (n = 698,098, aged 51-69) were followed during 1995-2001. On the basis of a central prescription registry, daily updated national capture on HT was determined. National Registers identified 4947 MI incidents. Poisson regression analyses estimated rate ratios (RRs). Overall, we found no increased risk [RR 1.03 (95% CI: 0.95-1.11)] of MI with the current HT compared with women who never used HT; age-stratified RR among women aged 51-54, 55-59, 60-64, and 65-69 years were 1.24 (1.02-1.51), 0.96 (0.82-1.12), 1.11 (0.97-1.27), and 0.92 (0.80-1.06), respectively. An increasing risk with longer duration was found for younger women, which was not observed with older age groups. In all age groups, the highest risk of MI was found with continuous HT regimen. No increased risk was found with unopposed oestrogen, cyclic combined therapy, or tibolone. Significantly lower risk was found with dermal route than oral unopposed oestrogen therapy (P = 0.04). No associations were found with progestagen type or oestrogen dose. CONCLUSION: In a National cohort study, we found that HT regimen and route of application could modify the influence of HT on the risk of MI.
Hormone therapy and risk of myocardial infarction: a national register study.
Løkkegaard E, Andreasen AH, Jacobsen RK, Nielsen LH, Agger C, Lidegaard Ø.
Gynaecological Clinic, Rigshospitalet, Copenhagen Ø, Denmark.
Comment in: Womens Health (Lond Engl). 2009 Jan;5(1):29-31.
AIM: To assess the risk of myocardial infarction (MI) as a result of hormone therapy (HT), with focus on the influence of age, duration of HT, various regimens and routes, progestagen type, and oestrogen dose. METHODS AND RESULTS: All healthy Danish women (n = 698,098, aged 51-69) were followed during 1995-2001. On the basis of a central prescription registry, daily updated national capture on HT was determined. National Registers identified 4947 MI incidents. Poisson regression analyses estimated rate ratios (RRs). Overall, we found no increased risk [RR 1.03 (95% CI: 0.95-1.11)] of MI with the current HT compared with women who never used HT; age-stratified RR among women aged 51-54, 55-59, 60-64, and 65-69 years were 1.24 (1.02-1.51), 0.96 (0.82-1.12), 1.11 (0.97-1.27), and 0.92 (0.80-1.06), respectively. An increasing risk with longer duration was found for younger women, which was not observed with older age groups. In all age groups, the highest risk of MI was found with continuous HT regimen. No increased risk was found with unopposed oestrogen, cyclic combined therapy, or tibolone. Significantly lower risk was found with dermal route than oral unopposed oestrogen therapy (P = 0.04). No associations were found with progestagen type or oestrogen dose. CONCLUSION: In a National cohort study, we found that HT regimen and route of application could modify the influence of HT on the risk of MI.
Facebook's Most Popular Menopause Doctor
Georgianna, 50
Medical Office Manager
Arcadia, CA
Medical Office Manager
Arcadia, CA
"It's wonderful having Dr. Miller in town. When I refer my patients to her I know they will receive both outstanding medical care and VIP treatment."
Dr. Bijan Pourat
Cardiologist
Beverly Hills, CA
Click here
to listen to Dr. Miller on 1480 KYOS.
Click here
to listen to Dr. Miller on 88.9 KRFC. NEW!
Disclaimer: All the information on this website is intended for educational purposes only, and should not be construed as personal medical advice. Dr. Miller encourages you to do your research and make your own health care decisions with the guidance of a qualified physician.
Contact
Dr. Shira Miller, The Integrative Center for Health & Wellness
562 S. San Vicente Blvd.
Los Angeles, CA 90048
Get Directions
562 S. San Vicente Blvd.
Los Angeles, CA 90048
Get Directions
- Phone: 310-734-8864
- Fax: 310-943-6345
- Email Us